Iclusig, a kinase inhibitor, received a positive opinion for use alongside low-intensity chemotherapy in adults with newly identified disease.
Intrinsic sensitivity to imatinib, based on measurement of inhibitory concentration 50% for imatinib, is variable in untreated patients with chronic myeloid leukemia (CML). This suggests that ...
Expert Rev Anticancer Ther. 2008;8(9):1387-1398. Expert Rev Anticancer Ther. 2008;8(9):1387-1398. © 2008 Expert Reviews Ltd. No writing assistance was utilized in ...
Beijing Infinite Intelligence Pharmaceutical Technology Co. Ltd. and Suzhou Fish-Summoning Biotechnology Co. Ltd. have identified compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to ...
Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia ...
Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for ...
Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has disclosed aromatic amine compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to be useful for the treatment of neurodegeneration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results